Cathelicidin peptide LL-37 modulates TREM-1 expression and inflammatory responses to microbial compounds.
Amatngalim. Gimano D GD; Nijnik. Anastasia A; Hiemstra. Pieter S PS; Hancock. Robert E W RE
Key Findings
- LL‑37 strongly suppresses combined TREM‑1 and TLR4‑driven inflammation in peripheral blood mononuclear cells
- LL‑37 reduces TREM‑1 expression on monocytes, contributing to its anti‑inflammatory action
- When peptidoglycan (a TLR2 ligand) is present, LL‑37 actually increases TREM‑1 expression and inflammation via the p38 MAPK pathway
- LL‑37 does not affect neutrophil degranulation, ROS production, or IL‑8 release
Practical Outcomes
- LL‑37 may be a promising template for anti‑inflammatory or anti‑endotoxin therapies, but its effects vary with the type of bacterial signal, so it isn’t ready for direct DIY dosing. For now, biohackers might focus on natural ways to raise endogenous LL‑37 (e.g., vitamin D, certain diets) while awaiting more human safety and dosing data.
Summary
The study shows that the natural human peptide LL‑37 can tone down some inflammation signals (especially when the immune system is hit by both TREM‑1 and TLR4 triggers) by lowering TREM‑1 levels on certain white blood cells, but it can also boost inflammation when the trigger is a bacterial wall piece called peptidoglycan. It doesn’t change how neutrophils release enzymes or reactive oxygen. This means LL‑37’s anti‑inflammatory effects depend on the exact type of microbial stimulus.
Abstract
Inflammatory diseases remain an important cause of morbidity and mortality. Cathelicidins are immunomodulatory and antimicrobial peptides with potent anti-endotoxic properties. Although the effects of the human cathelicidin LL-37 on cellular responses to Toll-like receptor (TLR) ligands have been investigated, its effects on responses to other pro-inflammatory stimuli have not been well studied. Triggering receptor expressed on myeloid cells (TREM-1) acts to amplify inflammatory responses and plays important roles in the pathogenesis of endotoxemia. In this work, the effects of LL-37 on responses to TREM-1 stimulation, alone and in the presence of a range of microbial compounds, were analyzed. It was shown that in peripheral blood mononuclear cells LL-37 strongly suppressed synergistic responses to TREM-1 and TLR4 stimulation, partly through the inhibition of TREM-1 expression on monocytes; similar effects were observed using the TLR2 ligand lipoteichoic acid. In contrast, LL-37 stimulated TREM-1 upregulation by peptidoglycan (PGN, TLR2 ligand that is also recognized via nucleotide-binding oligomerization domain containing 2 after fragmentation and intracellular uptake), as well as the responses to combined TREM-1 and PGN stimulation, possibly via the p38 mitogen-activated protein kinase pathway. LL-37 did not affect TREM-1-induced neutrophil degranulation or the production of reactive oxygen species and interleukin-8 by neutrophils. These findings provide further insight into the roles of LL-37 during inflammation and may have implications for its in vivo immunomodulatory properties and for the design of synthetic cathelicidin derivatives as anti-inflammatory and anti-endotoxic molecules.
Study Information
pubmed
2011
2011-10-01T00:00:00.000Z
10.1007/s10753-010-9248-6
33
74